{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:48Z","timestamp":1791316788794,"version":"4.3.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["Research Scholar Grant RSG-21-034-01-TBG"],"award-info":[{"award-number":["Research Scholar Grant RSG-21-034-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35 CA263816"],"award-info":[{"award-number":["R35 CA263816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U24 CA213274"],"award-info":[{"award-number":["U24 CA213274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Small cell lung cancer (SCLC) is difficult to treat due to its aggressiveness, early metastasis, and rapid development of resistance to chemotherapeutic agents. Here, we show that treatment with a dopamine D\n                    <jats:sub>2<\/jats:sub>\n                    receptor (D\n                    <jats:sub>2<\/jats:sub>\n                    R) agonist reduces tumour angiogenesis in multiple in vivo xenograft models of human SCLC, thereby reducing SCLC progression. An FDA-approved D\n                    <jats:sub>2<\/jats:sub>\n                    R agonist, cabergoline, also sensitized chemotherapy-resistant SCLC tumours to cisplatin and etoposide in patient-derived xenograft models of acquired chemoresistance in mice. Ex vivo, D\n                    <jats:sub>2<\/jats:sub>\n                    R agonist treatment decreased tumour angiogenesis through increased apoptosis of tumour-associated endothelial cells, creating a less favourable tumour microenvironment that limited cancer cell proliferation. In paired SCLC patient-derived specimens, D\n                    <jats:sub>2<\/jats:sub>\n                    R was expressed by tumour-associated endothelial cells obtained before treatment, but D\n                    <jats:sub>2<\/jats:sub>\n                    R was downregulated in SCLC tumours that had acquired chemoresistance. D\n                    <jats:sub>2<\/jats:sub>\n                    R agonist treatment of chemotherapy-resistant specimens restored expression of D\n                    <jats:sub>2<\/jats:sub>\n                    R. Activation of dopamine signalling is thus a new strategy for inhibiting angiogenesis in SCLC and potentially for combatting chemotherapy-refractory SCLC progression.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-07693-y","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:58:24Z","timestamp":1746791904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5342-4542","authenticated-orcid":false,"given":"Sk. Kayum","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Sahar","family":"Mortazavi Farsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britteny A.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathy","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-3465","authenticated-orcid":false,"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-0645","authenticated-orcid":false,"given":"Ying-Chun","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3948-4244","authenticated-orcid":false,"given":"Luke H.","family":"Hoeppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"7693_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"7693_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cllc.2016.05.014","volume":"17","author":"K Kahnert","year":"2016","unstructured":"Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC-state of the art and what does the future have in store? Clinical Lung Cancer. 2016;17:325\u2013333.","journal-title":"Clinical Lung Cancer"},{"key":"7693_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.lungcan.2011.08.004","volume":"75","author":"SP Riaz","year":"2012","unstructured":"Riaz SP, Luchtenborg M, Coupland VH, Spicer J, Peake MD, Moller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012;75:280\u20134.","journal-title":"Lung Cancer"},{"key":"7693_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2013.0011","volume":"11","author":"GP Kalemkerian","year":"2013","unstructured":"Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, et al. Small cell lung cancer. J Natl Compr Cancer Netw. 2013;11:78\u201398.","journal-title":"J Natl Compr Cancer Netw"},{"key":"7693_CR5","first-page":"271","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer J Clin. 2016;66:271\u201389.","journal-title":"CA: a cancer J Clin"},{"key":"7693_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346\u201360 e7.","journal-title":"Cancer Cell"},{"key":"7693_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289\u201397.","journal-title":"Nat Rev Cancer"},{"key":"7693_CR8","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.3390\/ijms24098129","volume":"24","author":"N McNamee","year":"2023","unstructured":"McNamee N, da Silva IP, Nagrial A, Gao B. Small-cell lung cancer-an update on targeted and immunotherapies.Int J Mol Sci.2023;24:8129","journal-title":"Int J Mol Sci."},{"key":"7693_CR9","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","volume":"30","author":"A Rossi","year":"2012","unstructured":"Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692\u20138.","journal-title":"J Clin Oncol"},{"key":"7693_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51\u201365.","journal-title":"Lancet Oncol"},{"key":"7693_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330.","journal-title":"J Clin Oncol"},{"key":"7693_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983\u20135.","journal-title":"Science"},{"key":"7693_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306\u20139.","journal-title":"Science"},{"key":"7693_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/380435a0","volume":"380","author":"P Carmeliet","year":"1996","unstructured":"Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435\u20139.","journal-title":"Nature"},{"key":"7693_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O\u2019Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439\u201342.","journal-title":"Nature"},{"key":"7693_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/1097-0061(200012)17:4<294::AID-YEA54>3.0.CO;2-5","volume":"17","author":"A Nasevicius","year":"2000","unstructured":"Nasevicius A, Larson J, Ekker SC. Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast. 2000;17:294\u2013301.","journal-title":"Yeast"},{"key":"7693_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359\u201371.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7693_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611\u201325.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7693_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1165\/ajrcmb.22.6.3779","volume":"22","author":"RJ Kaner","year":"2000","unstructured":"Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol. 2000;22:657\u201364.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"7693_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/shk.0b013e31804d1998","volume":"28","author":"T Lahm","year":"2007","unstructured":"Lahm T, Crisostomo PR, Markel TA, Wang M, Lillemoe KD, Meldrum DR. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock. 2007;28:4\u201314.","journal-title":"Shock"},{"key":"7693_CR21","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.5301\/jbm.5000148","volume":"30","author":"Q Lin","year":"2015","unstructured":"Lin Q, Xue L, Tian T, Zhang B, Guo L, Lin G, et al. Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer. Int J Biol Markers. 2015;30:e359\u201363.","journal-title":"Int J Biol Markers"},{"key":"7693_CR22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ejcts.2009.10.002","volume":"37","author":"K Nowak","year":"2010","unstructured":"Nowak K, Rafat N, Belle S, Weiss C, Hanusch C, Hohenberger P, et al. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardio Thorac Surg. 2010;37:758\u201363.","journal-title":"Eur J Cardio Thorac Surg"},{"key":"7693_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO;2-T","volume":"79","author":"P Salven","year":"1998","unstructured":"Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 1998;79:144\u20136.","journal-title":"Int J Cancer"},{"key":"7693_CR24","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/JTO.0b013e3181a97e31","volume":"4","author":"P Zhan","year":"2009","unstructured":"Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4:1094\u2013103.","journal-title":"J Thorac Oncol"},{"key":"7693_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1517\/14712590902817817","volume":"9","author":"J Jenab-Wolcott","year":"2009","unstructured":"Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009;9:507\u201317.","journal-title":"Expert Opin Biol Ther"},{"key":"7693_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ctrv.2013.11.009","volume":"40","author":"G Limaverde-Sousa","year":"2014","unstructured":"Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev. 2014;40:548\u201357.","journal-title":"Cancer Treat Rev"},{"key":"7693_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/cbt.19594","volume":"13","author":"C Aggarwal","year":"2012","unstructured":"Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?. Cancer Biol Ther. 2012;13:247\u201363.","journal-title":"Cancer Biol Ther"},{"key":"7693_CR28","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1200\/JCO.2009.23.7545","volume":"27","author":"L Horn","year":"2009","unstructured":"Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009;27:6006\u201311.","journal-title":"J Clin Oncol"},{"key":"7693_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.lungcan.2012.02.002","volume":"77","author":"G Mountzios","year":"2012","unstructured":"Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, et al. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer. 2012;77:146\u201350.","journal-title":"Lung Cancer"},{"key":"7693_CR30","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/j.cllc.2015.05.005","volume":"16","author":"R Petrioli","year":"2015","unstructured":"Petrioli R, Roviello G, Laera L, Luzzi L, Paladini P, Ghiribelli C, et al. Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experience. Clin Lung Cancer. 2015;16:e229\u201334.","journal-title":"Clin Lung Cancer"},{"key":"7693_CR31","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/annonc\/mdv065","volume":"26","author":"JL Pujol","year":"2015","unstructured":"Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. dagger Ann Oncol. 2015;26:908\u201314.","journal-title":"dagger Ann Oncol"},{"key":"7693_CR32","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1200\/JCO.2011.35.6923","volume":"29","author":"NE Ready","year":"2011","unstructured":"Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011;29:4436\u201341.","journal-title":"J Clin Oncol"},{"key":"7693_CR33","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/JTO.0b013e3181bbc540","volume":"4","author":"DR Spigel","year":"2009","unstructured":"Spigel DR, Greco FA, Zubkus JD, Murphy PB, Saez RA, Farley C, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol. 2009;4:1555\u201360.","journal-title":"J Thorac Oncol"},{"key":"7693_CR34","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","volume":"29","author":"DR Spigel","year":"2011","unstructured":"Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29:2215\u201322.","journal-title":"J Clin Oncol"},{"key":"7693_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cllc.2012.12.003","volume":"14","author":"DR Spigel","year":"2013","unstructured":"Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clin Lung Cancer. 2013;14:356\u201363.","journal-title":"Clin Lung Cancer"},{"key":"7693_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jnci\/djp200","volume":"101","author":"SM Lee","year":"2009","unstructured":"Lee SM, Woll PJ, Rudd R, Ferry D, O\u2019Brien M, Middleton G, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101:1049\u201357.","journal-title":"J Natl Cancer Inst"},{"key":"7693_CR37","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.2007.11.8109","volume":"25","author":"JL Pujol","year":"2007","unstructured":"Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol. 2007;25:3945\u201351.","journal-title":"J Clin Oncol"},{"key":"7693_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.lungcan.2012.09.019","volume":"79","author":"JY Han","year":"2013","unstructured":"Han JY, Kim HY, Lim KY, Han JH, Lee YJ, Kwak MH, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013;79:137\u201342.","journal-title":"Lung Cancer"},{"key":"7693_CR39","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2014.57.3105","volume":"33","author":"NE Ready","year":"2015","unstructured":"Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled Phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015;33:1660\u20135.","journal-title":"J Clin Oncol"},{"key":"7693_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/JTO.0b013e31821529c3","volume":"6","author":"BJ Schneider","year":"2011","unstructured":"Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6:1117\u201320.","journal-title":"J Thorac Oncol"},{"key":"7693_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.lungcan.2012.03.009","volume":"77","author":"DR Spigel","year":"2012","unstructured":"Spigel DR, Greco FA, Rubin MS, Shipley D, Thompson DS, Lubiner ET, et al. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer. 2012;77:359\u201364.","journal-title":"Lung Cancer"},{"key":"7693_CR42","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1200\/JCO.2007.12.3083","volume":"25","author":"AM Arnold","year":"2007","unstructured":"Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007;25:4278\u201384.","journal-title":"J Clin Oncol"},{"key":"7693_CR43","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/JTO.0b013e3181e2fcb0","volume":"5","author":"SS Ramalingam","year":"2010","unstructured":"Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010;5:1279\u201384.","journal-title":"J Thorac Oncol"},{"key":"7693_CR44","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/JTO.0b013e3181f0bd78","volume":"5","author":"BJ Gitlitz","year":"2010","unstructured":"Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010;5:1835\u201340.","journal-title":"J Thorac Oncol"},{"key":"7693_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2016.04.002","volume":"96","author":"JY Han","year":"2016","unstructured":"Han JY, Kim HY, Lim KY, Hwangbo B, Lee JS. A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer. 2016;96:108\u201312.","journal-title":"Lung Cancer"},{"key":"7693_CR46","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s11684-021-0916-8","volume":"16","author":"J Shi","year":"2022","unstructured":"Shi J, Cheng Y, Wang Q, Li K, Wu L, Han B, et al. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202). Front Med. 2022;16:766\u201372.","journal-title":"Front Med"},{"key":"7693_CR47","doi-asserted-by":"publisher","first-page":"11133","DOI":"10.2147\/CMAR.S275624","volume":"12","author":"PF Song","year":"2020","unstructured":"Song PF, Xu N, Li Q. Efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage SCLC and the prognostic significance of common adverse reactions. Cancer Manag Res. 2020;12:11133\u201343.","journal-title":"Cancer Manag Res"},{"key":"7693_CR48","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.7150\/jca.20850","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Liu Q, Liao Q, Zhao Y. Potential roles of peripheral dopamine in tumor immunity. J Cancer. 2017;8:2966\u201373.","journal-title":"J Cancer"},{"key":"7693_CR49","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/0008-5472.CAN-08-4289","volume":"69","author":"D Chakroborty","year":"2009","unstructured":"Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res. 2009;69:3727\u201330.","journal-title":"Cancer Res"},{"key":"7693_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1750-2187-3-14","volume":"3","author":"R Bhattacharya","year":"2008","unstructured":"Bhattacharya R, Sinha S, Yang SP, Patra C, Dutta S, Wang E, et al. The neurotransmitter dopamine modulates vascular permeability in the endothelium. J Mol Signal. 2008;3:14.","journal-title":"J Mol Signal"},{"key":"7693_CR51","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1242\/jcs.053124","volume":"122","author":"S Sinha","year":"2009","unstructured":"Sinha S, Vohra PK, Bhattacharya R, Dutta S, Sinha S, Mukhopadhyay D. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J Cell Sci. 2009;122:3385\u201392.","journal-title":"J Cell Sci"},{"key":"7693_CR52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/87895","volume":"7","author":"S Basu","year":"2001","unstructured":"Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor. Nat Med. 2001;7:569\u201374.","journal-title":"Nat Med"},{"key":"7693_CR53","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1158\/0008-5472.CAN-04-1600","volume":"64","author":"S Basu","year":"2004","unstructured":"Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, et al. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor\/vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 2004;64:5551\u20135.","journal-title":"Cancer Res"},{"key":"7693_CR54","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-07-1778","volume":"14","author":"C Sarkar","year":"2008","unstructured":"Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res. 2008;14:2502\u201310.","journal-title":"Clin Cancer Res"},{"key":"7693_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s42003-018-0050-6","volume":"1","author":"SK Alam","year":"2018","unstructured":"Alam SK, Astone M, Liu P, Hall SR, Coyle AM, Dankert EN, et al. DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKalpha-dependent cell migration. Commun Biol. 2018;1:43.","journal-title":"Commun Biol"},{"key":"7693_CR56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41416-020-0923-6","volume":"123","author":"SK Alam","year":"2020","unstructured":"Alam SK, Wang L, Ren Y, Hernandez CE, Kosari F, Roden AC. et al. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation. Br J Cancer.2020;123:819\u2013832.","journal-title":"Br J Cancer."},{"key":"7693_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00370-3","volume":"7","author":"SK Alam","year":"2023","unstructured":"Alam SK, Wang L, Zhu Z, Hoeppner LH. IKKalpha promotes lung adenocarcinoma growth through ERK signaling activation via DARPP-32-mediated inhibition of PP1 activity. NPJ Precis Oncol. 2023;7:33.","journal-title":"NPJ Precis Oncol"},{"key":"7693_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41388-021-02028-5","volume":"41","author":"SK Alam","year":"2022","unstructured":"Alam SK, Zhang Y, Wang L, Zhu Z, Hernandez CE, Zhou Y, et al. DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. Oncogene. 2022;41:83\u201398.","journal-title":"Oncogene"},{"key":"7693_CR59","doi-asserted-by":"publisher","first-page":"L185","DOI":"10.1152\/ajplung.00274.2010","volume":"302","author":"PK Vohra","year":"2012","unstructured":"Vohra PK, Hoeppner LH, Sagar G, Dutta SK, Misra S, Hubmayr RD, et al. Dopamine inhibits pulmonary edema through the VEGF-VEGFR2 axis in a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2012;302:L185\u201392.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7693_CR60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.molonc.2014.08.008","volume":"9","author":"LH Hoeppner","year":"2015","unstructured":"Hoeppner LH, Wang Y, Sharma A, Javeed N, Van Keulen VP, Wang E, et al. Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol. 2015;9:270\u201381.","journal-title":"Mol Oncol"},{"key":"7693_CR61","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1172\/JCI33125","volume":"118","author":"D Chakroborty","year":"2008","unstructured":"Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, Basu S. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest. 2008;118:1380\u20139.","journal-title":"J Clin Invest"},{"key":"7693_CR62","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/539706","volume":"2010","author":"J Tilan","year":"2010","unstructured":"Tilan J, Kitlinska J. Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J Oncol. 2010;2010:539706.","journal-title":"J Oncol"},{"key":"7693_CR63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","volume":"31","author":"EE Gardner","year":"2017","unstructured":"Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31:286\u201399.","journal-title":"Cancer Cell"},{"key":"7693_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-33","volume":"1","author":"AT Wang","year":"2012","unstructured":"Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1:33.","journal-title":"Syst Rev"},{"key":"7693_CR65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000058049","volume":"46","author":"HK Baas","year":"2001","unstructured":"Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson\u2019s disease. Eur Neurol. 2001;46:18\u201323.","journal-title":"Eur Neurol"},{"key":"7693_CR66","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/09513590.2012.730578","volume":"29","author":"T Kalampokas","year":"2013","unstructured":"Kalampokas T, Creatsas G, Kalampokas E. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review. Gynecol Endocrinol. 2013;29:98\u2013100.","journal-title":"Gynecol Endocrinol"},{"key":"7693_CR67","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1210\/jc.2012-3126","volume":"98","author":"RA Feelders","year":"2013","unstructured":"Feelders RA, Hofland LJ. Medical treatment of Cushing\u2019s disease. J Clin Endocrinol Metab. 2013;98:425\u201338.","journal-title":"J Clin Endocrinol Metab"},{"key":"7693_CR68","volume":"2011","author":"H Scholz","year":"2011","unstructured":"Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011;2011:CD006009.","journal-title":"Cochrane Database Syst Rev"},{"key":"7693_CR69","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2165\/00003495-200464180-00015","volume":"64","author":"MP Curran","year":"2004","unstructured":"Curran MP, Perry CM. Cabergoline : a review of its use in the treatment of Parkinson\u2019s disease. Drugs. 2004;64:2125\u201341.","journal-title":"Drugs"},{"key":"7693_CR70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58\u201362.","journal-title":"Science"},{"key":"7693_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12865-014-0036-1","volume":"15","author":"L Lin","year":"2014","unstructured":"Lin L, Couturier J, Yu X, Medina MA, Kozinetz CA, Lewis DE. Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells. BMC Immunol. 2014;15:36.","journal-title":"BMC Immunol"},{"key":"7693_CR72","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?. Oncoimmunology. 2017;7:e1364828.","journal-title":"Oncoimmunology"},{"key":"7693_CR73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391\u2013400.","journal-title":"Nat Rev Drug Discov"},{"key":"7693_CR74","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.devcel.2016.03.015","volume":"37","author":"W Ye","year":"2016","unstructured":"Ye W. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. Dev Cell. 2016;37:114\u201325.","journal-title":"Dev Cell"},{"key":"7693_CR75","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131\u20138.","journal-title":"Oncologist"},{"key":"7693_CR76","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/annonc\/mdv065","volume":"26","author":"JL Pujol","year":"2015","unstructured":"Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, et al. Randomized phase II\u2013III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol. 2015;26:908\u201314.","journal-title":"Ann Oncol"},{"key":"7693_CR77","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/JTO.0b013e3181f77b6e","volume":"5","author":"S Jalal","year":"2010","unstructured":"Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol. 2010;5:2008\u201311.","journal-title":"J Thorac Oncol"},{"key":"7693_CR78","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542\u201350.","journal-title":"N Engl J Med"},{"key":"7693_CR79","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/carcin\/bgac045","volume":"43","author":"CE Grant","year":"2022","unstructured":"Grant CE, Flis AL, Ryan BM. Understanding the role of dopamine in cancer: past, present and future. Carcinogenesis. 2022;43:517\u201327.","journal-title":"Carcinogenesis"},{"key":"7693_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1267\/ahc.22-00031","volume":"55","author":"T Ito","year":"2022","unstructured":"Ito T, Kudoh S, Fujino K, Sanada M, Tenjin Y, Saito H, et al. Pulmonary neuroendocrine cells and small cell lung carcinoma: immunohistochemical study focusing on mechanisms of neuroendocrine differentiation. Acta Histochem Cytochem. 2022;55:75\u201383.","journal-title":"Acta Histochem Cytochem"},{"key":"7693_CR81","doi-asserted-by":"publisher","first-page":"77319","DOI":"10.18632\/oncotarget.12964","volume":"7","author":"X Xie","year":"2016","unstructured":"Xie X, Luo X, Xie M, Liu Y, Wu T. Risk of lung cancer in Parkinson\u2019s disease. Oncotarget. 2016;7:77319\u201325.","journal-title":"Oncotarget"},{"key":"7693_CR82","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"key":"7693_CR83","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000499470","volume":"109","author":"RS Auriemma","year":"2019","unstructured":"Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A. Dopamine agonists: from the 1970s to today. Neuroendocrinology. 2019;109:34\u201341.","journal-title":"Neuroendocrinology"},{"key":"7693_CR84","doi-asserted-by":"publisher","first-page":"H1554","DOI":"10.1152\/ajpheart.00272.2004","volume":"287","author":"C Sarkar","year":"2004","unstructured":"Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol. 2004;287:H1554\u201360.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7693_CR85","doi-asserted-by":"publisher","first-page":"8358","DOI":"10.1080\/21655979.2021.1987066","volume":"12","author":"L You","year":"2021","unstructured":"You L, Jiang H. Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS). Bioengineered. 2021;12:8358\u201369.","journal-title":"Bioengineered"},{"key":"7693_CR86","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","volume":"4","author":"R Meuwissen","year":"2003","unstructured":"Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4:181\u20139.","journal-title":"Cancer Cell"},{"key":"7693_CR87","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41388-023-02929-7","volume":"43","author":"MG Oser","year":"2024","unstructured":"Oser MG, MacPherson D, Oliver TG, Sage J, Park KS. Genetically-engineered mouse models of small cell lung cancer: the next generation. Oncogene. 2024;43:457\u201369.","journal-title":"Oncogene"},{"key":"7693_CR88","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1158\/0008-5472.CAN-09-4228","volume":"70","author":"BE Schaffer","year":"2010","unstructured":"Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010;70:3877\u201383.","journal-title":"Cancer Res"},{"key":"7693_CR89","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, et al. MYC Drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38:60\u201378.e12.","journal-title":"Cancer Cell"},{"key":"7693_CR90","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu G, Guthrie MR, Bohm S, Bragelmann J, Can I, Ballieu PM, et al. MYC Drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31:270\u201385.","journal-title":"Cancer Cell"},{"key":"7693_CR91","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1101\/gad.328336.119","volume":"33","author":"MG Oser","year":"2019","unstructured":"Oser MG, Sabet AH, Gao W, Chakraborty AA, Schinzel AC, Jennings RB, et al. The KDM5A\/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 2019;33:1718\u201338.","journal-title":"Genes Dev"},{"key":"7693_CR92","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-10-2441","volume":"17","author":"M Moreno-Smith","year":"2011","unstructured":"Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, et al. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011;17:3649\u201359.","journal-title":"Clin Cancer Res"},{"key":"7693_CR93","doi-asserted-by":"publisher","first-page":"20730","DOI":"10.1073\/pnas.1108696108","volume":"108","author":"D Chakroborty","year":"2011","unstructured":"Chakroborty D, Sarkar C, Yu H, Wang J, Liu Z, Dasgupta PS, et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci USA. 2011;108:20730\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7693_CR94","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109:17561\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7693_CR95","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Sci Transl Med. 2017;9:eaak9679","journal-title":"Sci Transl Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07693-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:03:20Z","timestamp":1746795800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07693-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7693"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07693-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All studies described in this manuscript were performed in accordance with the relevant guidelines and regulations. For studies involving human subjects, written informed consent was obtained from each of the individual human subjects prior to inclusion in this study, and the Mayo Clinic Institutional Review Board Committee approved this study. All studies involving animals were approved by the University of Minnesota Institutional Animal Care and Use Committee and performed in accordance with these approved guidelines (Protocol: 2410-42469A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"370"}}